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Human neutrophil antigen (HNA)-typed granulocyte panels are 
widely used to screen for the presence of HNA antibodies and to 
determine antibody specificity. Many laboratories screen donors 
for HNA genotypes using low-throughput methods such as 
allele-specific polymerase chain reaction (PCR), PCR–restriction 
fragment–length polymorphism, and multiplex PCR. In the 
present study, we used a high-resolution melting (HRM) analysis 
to determine HNA genotypes. For the HRM analysis, purified 
genomic DNA samples were amplified via PCR with HNA-specific 
primers. Nucleotide substitutions in genes encoding HNAs were 
differentiated on the basis of the HRM curves, and the results of HRM 
and DNA sequencing analyses were determined to be in complete 
agreement. The gene frequency of HNA-1a, -1b, -1c, -3a, -3b, 
-4a, -4b, -5a, and -5b in the Japanese population was consistent 
with the previous reports. Our results suggest that HRM analysis 
can be used for genotyping HNA antigens determined by single 
nucleotide substitutions. Immunohematology 2015;31:7–13.
Key Words: neutrophil, HNA, antibody, genotyping, high-
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Evidence indicates that leukocyte antibodies are one of the 
primary causes of nonhemolytic transfusion reactions, par-
ticularly in transfusion-related acute lung injury (TRALI).1–4 
Human leukocyte antigen (HLA) class I,1,2,5 HLA class II,6–9 
and human neutrophil antigen (HNA)10–15 antibodies have 
been associated with nonhemolytic transfusion reactions. 
Therefore, it is important to detect such antibodies in blood 
components used for transfusion.
HNAs have been classified into five systems (HNA-1, 
HNA-2, HNA-3, HNA-4, and HNA-5), and differences 
between these HNA polymorphisms can result in several 
alloimmunization responses. HNA-1 comprises the following 
antigens: HNA-1a, HNA-1b, HNA-1c, and HNA-1d; these 
are specifically expressed on neutrophils. Antibodies against 
HNA-1 are frequently thought to be the cause of alloimmune 
neutropenia (ANN), autoimmune neutropenia, and TRALI.16–18 
HNA-2 is represented by a single antigen and is expressed on 
neutrophils in Caucasian (97%), African American (95%), 
and Japanese (88%) populations.19,20 Polymorphism of this 
antigen has not been reported. Antibodies against this antigen 
are associated with ANN, autoimmune neutropenia, febrile 
transfusion reactions, and TRALI.12,21–23 HNA-3, comprising 
HNA-3a and HNA-3b, is expressed on granulocytes, 
lymphocytes, platelets, endothelial cells, kidney, spleen, and 
placental cells.24 Alloantibodies to HNA-3a are associated with 
occasional cases of febrile transfusion reactions,25 ANN,26 and 
serious cases of TRALI.14,27,28 The HNA-4 and HNA-5 antigens 
reside on the subunits of the β-2 integrin family (CD11a and 
CD11b, respectively). HNA-4 is expressed on granulocytes, 
monocytes, and NK cells, whereas HNA-5 is expressed on 
all leukocytes.17 Moreover, alloantibodies against HNA-4a 
can cause ANN, but those specific for HNA-5a have not been 
clinically associated with neutropenia.29
The detection of antibodies against HNAs primarily relies 
on cell-based assays, the granulocyte immunofluorescence 
test (GIFT), and granulocyte agglutination test (GAT). The 
International Society of Blood Transfusion Working Party on 
Granulocyte Immunobiology recommends GIFT and GAT as 
reference methods for detecting HNA antibodies.30 Although 
cells could be stored for a week following fixation for use 
with GIFT, they were difficult to use in high-sensitivity flow 
cytometry analysis because normal human sera revealed high 
background reactivity to neutrophils.
Genotyping via high-resolution melting (HRM) analysis 
can be used to rapidly predict the HNA antigen status of cells 
that could be used as panel cells in GIFT and GAT. In the 
field of genotyping, HRM analysis sensitively and specifically 
detects a single nucleotide change in a gene.31 Further, HRM 
analysis is a simpler and more rapid genotyping method 
compared with allele-specific polymerase chain reaction 
(PCR), PCR–restriction fragment–length polymorphism, and 
multiplex PCR.32 In the present study, we used HRM analysis 
to genotype for HNAs.
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Materials and Methods
Blood Samples and DNA Preparation
Whole blood anticoagulated with ethylenediamine-
tetraacetic acid was collected from healthy blood donors 
and used as leukocyte samples for genotyping HNAs. DNA 
was prepared using the QIAsymphony instrument and 
QIAsymphony DNA Mini kit (Qiagen, Hilden, Germany). This 
research project was approved by the ethics committee of the 
Japanese Red Cross Society Blood Service Headquarters.
Primer Selection
We performed HNA-1, HNA-3, HNA-4, and HNA-5 
genotyping using a PCR-HRM method.31 HNA-1a, HNA-1b, 
and HNA-1c were encoded by FCGR3B*1, FCGR3B*2, and 
FCGR3B*3 (GenBank accession number: NC_000001.10), 
respectively. Because FCGR3B highly resembles FCGR3A,18 
which encodes FcγR3a, we first amplified FCGR3B-specific 
DNA to avoid the contamination of FCGR3A DNA before 
performing PCR-HRM analysis for HNA-1 genotyping; we 
developed a pair of primers [5-GGCACATATGGGGACAAT-3, 
called “FCGR3B forward” (nucleotide position in FCGR3B, 
6616–6633), and 3-GAGCTCACTGCAACTTCTG-5, called 
“FCGR3B reverse” (nucleotide position in FCGR3B, 7604–
7622)] that were designed to amplify the FCGR3B fragment, 
including the five polymorphic sites described subsequently 
but not the FCGR3A fragment. FCGR3B*1 differs from 
FCGR3B*2 at five nucleotide positions, and a single 
nucleotide polymorphism (SNP) differentiates FCGR3B*2 
from FCGR3B*3 (Table 1). HNA-1a differs from HNA-1b 
at five nucleotide positions (141, 147, 227, 277, and 349), 
which results in four amino acid residue changes at positions 
36, 65, 82, and 106 in the membrane-distal domain of the 
glycoprotein. Furthermore, HNA-1b differs from HNA-1c at 
nucleotide position 266 alone, resulting in the substitution 
of Ala to Asp at position 78 (Table 1). Recently, HNA-1d was 
proposed as an additional allele of the HNA-1 system.18 Reil 
et al. performed epitope mapping experiments using human 
embryonic kidney cells that express different recombinant 
variants of FcγRIIIb. We designed several primer sets to 
amplify the polymorphic sites of HNA-1, HNA-3, HNA-4, and 
HNA-5. The primer sequences are shown in Table 2. These 
primers were synthesized using standard phosphoramidite 
chemistry (Life Technologies, Carlsbad, CA).
PCR Amplification of FCGR3B Fragment Prior to 
HNA-1 Genotyping
Because nucleotide sequences of FCGR3A and FCGR3B 
are very similar, we developed a PCR pre-amplification system 
for HNA-1 to avoid the amplification of the FCGR3A fragment 
prior to HNA-1 genotyping. Each PCR contained 1 µL 
genomic DNA, 1 µL forward primer (5 µmol/L), 1 µL reverse 
primer (5 µmol/L), 8.5 µL RNase-free water (Qiagen), and 
12.5 µL PrimeSTAR Max DNA polymerase premix (Takara, 
Seta, Japan) in a final volume of 25 µL. PCR amplification was 
performed with initial denaturation at 95°C for 5 minutes, 
followed by 35 cycles of 10 seconds at 95°C, at 55°C for 5 
seconds, and at 72°C for 10 seconds. Amplicons were purified 
using Diffinity RapidTip2 (Sigma, Deisenhofen, Germany).
PCR Amplification for Genotyping of HNA-1 to -5
This assay used the Type-it HRM Kit (Qiagen). Each PCR 
contained 1 µL DNA, 1 µL forward primer (5 µmol/L), 1 µL 
reverse primer (5 µmol/L), 8.5 µL RNase-free water (Qiagen), 
and 12.5 μL of a 2× HRM PCR master mix (Qiagen). The 
purified amplicons described earlier were used as templates 
for the genotyping of HNA-1, and genomic DNA was used for 
the genotyping of the other HNAs. The final reaction volume 
was 25 µL. A Roter-Gene Q (Qiagen) instrument was used. 
PCR amplification was performed with initial denaturation 
at 95°C for 5 minutes, followed by 40 cycles at 95°C for 10 
seconds, at 52°C for 30 seconds, and at 72°C for 10 seconds, 
with data acquisition during the 72°C step.
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Table 1. Alleles of FcγIIIb with location of single nucleotide polymorphisms and resulting amino acid changes
Nucleotide position
Antigen Allele 141* 147* 227* 266* 277* 349*
HNA-1a FCRG3B*01 AGG (p.Arg36) CTC (p.Leu38) AAC (p.Asn65) GCT (p.Ala78) GAC (p.Asp82) GTC (p.Val106)
HNA-1b FCRG3B*02 AGC (p.Ser36) CTT (p.Leu38) AGC (p.Ser65) GCT (p.Ala78) AAC (p.Asn82) ATC (p.Ile106)
HNA-1c FCRG3B*03 AGC (p.Ser36) CTT (p.Leu38) AGC (p.Ser65) GAT (p.Asp78) AAC (p.Asn82) ATC (p.Ile106)
HNA-1d FCRG3B*02 AGC(p.Ser36) CTC (p.Leu38) AGC (p.Ser65) GCT (p.Ala78) AAC (p.Asn82) ATC (p.Ile106)
*The underlined letters correspond to the position of the single nucleotide polymorphisms.
Note that for HNA-1d, amino acid positions and nucleotide positions were estimated according to the reactivity of the antisera against HNA-1d as reported by 
Reil et al.18
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Creation of Positive Control Plasmid for Genotyping
Synthetic DNA fragments (Fig. 1A–D) were cloned into 
the pCR2.1 TOPO plasmid (Life Technologies, Carlsbad, CA) 
and served as positive controls.
HRM Analysis
For HRM analysis, amplified samples bound to the fluo-
rescent dye were heated from 65°C to 95°C. The temperature 
was increased by 0.1°C/second at each step using the Roter-
Gene Q and covered the full range of expected melting points. 
HRM data were analyzed using the Roter-Gene Q software. 
Fluorescence intensity values were normalized between 0 
percent and 100 percent by defining linear baselines before and 
after the melting transition of each sample. The fluorescence 
of each acquisition was obtained from HRM curves and was 
HNA genotyping using real-time PCR and HRM
Table 2. DNA sequences of primers used in polymerase chain 
reaction and high-resolution melting analyses






























Fig. 1. Outlines of high-resolution melting analysis for HNA-1 to HNA-5 genotyping. The structures of responsible exons of each human 
neutrophil antigen (HNA), the sequences of synthetic DNA fragments used in high-resolution melting (HRM) analysis as positive controls, 
and the location of each single nucleotide polymorphism (SNP) of HNA alleles are presented. Arrows indicate the primers were used. The 
regions with the SNP are highlighted in each DNA sequence. The nucleotide position for each SNP is shown above the highlight. The regions 
with the SNPs in different alleles are shown below each synthetic DNA fragment. Polymerase chain reaction (PCR) amplification regions of 
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calculated as the percentage of fluorescence between the top 
and bottom baselines of each acquisition temperature, with a 
confidence threshold of 80 percent of the controls.
Statistical Analysis
Genotype and allele frequencies were calculated by 
the counting method. The validity of the Hardy-Weinberg 
equilibrium was tested by calculating the expected number 
of subjects for each genotype. Agreement of the observed 
and expected genotypes, based on the Hardy-Weinberg 
equilibrium, was determined using the χ2 test. The level of 
statistical significance was set at p < 0.05.
Results
HRM Analysis for Genotyping of HNAs
In the field of DNA-based genotyping, HRM analysis was 
developed as a novel method for detecting a single nucleotide 
change in a gene.31 Before performing HRM analysis, the target 
sequence is amplified in the presence of a double-stranded 
DNA-binding fluorescent dye, and the melting temperature 
(Tm) is increased from a lower to a higher temperature for the 
HRM analysis. Differences in the gene sequences between the 
heterozygous and homozygous genotypes lead to differences 
in Tm. Heterozygous genotypes tend to have lower Tm than 
homozygous genotypes, and, consequently, the overall HRM 
curves will shift to the left. The differences in the HRM curves 
were determined using the Roter-Gene Q software.
To confirm validity of HRM analysis for genotyping 
HNA-1, we amplified the control plasmids of each HNA-1 
allele (a/a, b/b, c/c, a/b, a/c, and b/c) and analyzed them 
using the Roter-Gene Q software. Because four nucleotide 
substitutions are involved in HNA-1 polymorphism, we set 
up a PCR system to categorize the “1a,” “1b,” and “1c” alleles 
based on the SNPs at positions 266 and 277. Figure 2A 
presents the representative HRM curves of synthesized DNA 
samples containing 1a, 1b, or 1c sequences. The melting curve 
shift for each of the synthetic DNA samples was estimated 
using Roter-Gene Q software, and these curves successfully 
defined each HNA-1 genotype. Subsequently, we used these 
curves as standard allotype-specific curves. With regard to 
HNA-1 genotyping, we first pre-amplified HNA-1–specific 
PCR amplicons and used these amplicons as templates for 
HNA-1 genotyping to avoid amplification of FCGR3A, whose 
DNA sequence highly resembles that of HNA-1. The absence 
of contamination of FCGR3A in the amplicons was confirmed 
using 15 representative genomic DNA samples derived from 
blood donors based on the following two points: (1) the 
amplicons revealed only FCGR3B-specific bands on agarose 
gel electrophoresis, and (2) subsequent DNA sequence analysis 
revealed that the amplicons were derived from FCGR3B. After 
excluding the possibility of contamination of FCGR3A DNA, 
we genotyped these 15 genomic DNA samples using the PCR-
HRM method. Following analysis of all samples, samples 6, 7, 
and 2 were determined as HNA-1a/1a, HNA-1b/1b, and HNA-
1a/1b, respectively (data not shown). The results of HRM 
analysis were in complete agreement with the sequencing data. 
Using the two different sets of HRM analysis, we successfully 
determined the genotypes of the three HNA-1 alleles.
Then, we analyzed HNA-3 (a/a, b/b, and a/b), HNA-4 
(a/a, b/b, and a/b), and HNA-5 (a/a, b/b, and a/b). The HRM 
curves of HNA-3 (Fig. 3A), HNA-4 (Fig. 3B), and HNA-5 
(Fig. 3C) clearly identified the individual genotypes using the 
synthetic DNA samples, and the results for 15 blood donors 
completely coincided with the DNA sequence analyses (data 
not shown). Therefore, HRM analysis successfully detected all 
the HNA polymorphisms.
Frequencies of HNA Genotypes Among Japanese 
Blood Donors
Having demonstrated that HRM analysis can be used 
to determine HNA genotypes, we subsequently genotyped 
500 Japanese individuals for HNA-1, HNA-3, HNA-4, and 
HNA-5 using HRM analysis and calculated the genotype 
frequency (Table 3) and the allele frequency (Table 4) of the 
Fig. 2. High-resolution melting analysis for HNA-1d allele. The 
synthetic DNA samples representing each HNA-1 were amplified 
using the primer set, which distinguished the changes at nucleotides 
266 and 277, and were analyzed using high-resolution melting 
(HRM). Six representative HRM curves (a/a, a/b, a/c, b/b, b/c, and 
c/c) are shown.
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HNA genotyping using real-time PCR and HRM
HNA system in Japan. The deviation of the observed numbers 
of genotypes from the expected numbers on the basis of the 
Hardy-Weinberg equilibrium was not statistically significant 
(Table 3). The occurrence of HNA-1 to -5 was similar to that 
reported elsewhere.33–35
Discussion
HRM is a very attractive, advanced, fast, and cost-effective 
SNP genotyping technology based on the analysis of the 
melting profile of PCR products, using intercalating fluorescent 
dyes to monitor the transition from double-stranded to single-
stranded (melted) DNA. This method was used to confirm 
HLA genotypic identity between unrelated individuals 
before allogeneic hematopoietic stem-cell transplantation.32,36 
Subsequently, several blood group antigens, including some 
in the Duffy, Kidd, and Diego blood group systems, were also 
genotyped using HRM analysis.37 Further, SNPs in the genes 
encoding human platelet antigens 1–6 and 15 were analyzed 
using HRM analysis.38 Thus, HRM analysis is a useful method 
for genotyping SNPs. In the present study, we applied HRM 
analysis to HNA genotyping and clearly genotyped and 
distinguished homozygous from heterozygous HNA alleles 
(Fig. 3).
Knowledge of HNA frequency is important for predicting 
the risk of alloimmunization to HNA. Previous studies 
had reported the frequency of HNA-1 to HNA-5 (except 
HNA-1d) among the Japanese population.18,33,34 The results 
reported here, using a different method, are consistent with 
these findings (Tables 3 and 4). The frequency of HNA-1d 
has not been reported previously. The HNA-1 system has 
three FCGR3B alleles. FCGR3B*01 encodes only one antigen 
(HNA-1a), while FCGR3B*02 and FCGR3B*03 encode two 
antigens each (HNA-1b and HNA-1d, and HNA-1b and HNA-
1c, respectively). Because the occurrence of HNA-1c was not 
observed in this study, the frequency of HNA-1d was similar 
to that of HNA-1b.
Occasionally, the contamination of PCR products interferes 
with genotype testing. HRM analysis determines genotypes of 
individual test samples using a real-time PCR instrument with 
a sample cap piercing feature, which eliminates a potential 
source of contamination.
The frequency of HNA-1 among the Japanese population 
considerably differs from that of Caucasians, who express 
HNA-1b more frequently than HNA-1a.34 Additionally, the 












































































HNA = human neutrophil antigen.
Table 4. HNA alleles among Japanese blood donors










HNA = human neutrophil antigen.
Fig. 3. High-resolution melting analysis of HNA-3, HNA-4, and 
HNA-5. Synthetic DNA samples were amplified and analyzed 
using high-resolution melting (HRM). HRM curves for each human 
neutrophil antigen (HNA) and its corresponding genotypes are 
presented in the following panels: (A) heterozygous HNA-3a/3b, 
homozygous HNA-3b/3b, and homozygous HNA-3a/3a; (B) hetero-
zygous HNA-4a/4b, homozygous HNA-4b/4b, and homozygous 
HNA-4a/4a; and (C) heterozygous HNA-5a/5b, homozygous HNA-
































































































12 IMMUNOHEMATOLOGY, Volume 31, Number 1, 2015
frequency of HNA-3b seems to be higher in the Japanese pop-
ulation than in Caucasians.34,39,40 This observation suggests a 
higher risk of alloimmunization for individuals homozygous 
for HNA-3b by exposure to the HNA-3a antigen during 
transfusion or pregnancy. Detection of antibodies against 
HNA-3a was infrequent in Japanese patients with TRALI, 
however. Therefore, additional factors specific for the Japanese 
population may elicit antibodies against HNA-3a.
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